E-prescribing Reduces Diabetes-Related Adverse Drug Events

March 24th, 2017 By: David Gutierrez

E-PrescribingAccording to research published in Medical Care, the use of electronic prescriptions with diabetes patients is associated with positive patient outcomes.  In the observational study, researchers found that the use of e-prescribing is associated with hospitalization or emergency department (ED) visits for hypoglycemia or diabetes-related adverse drug events.  In the study, a group of 3.1 million Medicare Part D enrolled beneficiaries older than age 66 with diabetes and at least 90 days of anti-diabetic medications were examined. They found that diabetes patients with more than 75% of their medications prescribed electronically had 21 adverse drug events per 1,000 Medicare Part D beneficiaries.  Beneficiaries with lower e-prescribing levels had significantly higher numbers of adverse drug events.  Authors found a ‘robust association between the greater use of electronic prescriptions in the outpatient setting and the lower risk of an inpatient or ED visit for an adverse drug among Medicare beneficiaries with diabetes in their adjusted analysis.’  The study was funded by the Agency for Healthcare Research and Quality.

RxNT’s e-prescribing solution is one of the first cloud-based ePrescribers introduced to the market over 18 years ago, and has continued to offer flexibility and cost-effective solutions to healthcare providers of all sizes.  Our easy-to-use eRx (ePrescriber) can be used as a standalone solution or can be fully integrated into RxNT’s electronic health records and practice management solutions.  To learn more about RxNT, call us at 800-943-7968 option 3, email us at Sales@RxNT.com, or click the “Learn More” button below.

Request A Demo

David Gutierrez

Posted in Blogs
Fill out this form to talk with one of RxNT's Team Members to schedule a demo or learn more about RxNT's solutions.
First Name:

Last Name:*

Practice Name:

State of Practice:

Office Phone:*

Email Address:*

Product(s) of Interest:







RxNT